Objective To investigate whether gender is associated with use of hypnotics or sedatives and with different types of hypnotics or sedatives in older people after adjustment for age, socioeconomic status (i.e., education) and co-morbidity (i.e., number of other drugs). Setting Sweden Method We conducted a register-based analysis of data on gender, age, dispensed drugs, and education from people aged 75-89 years registered in the Swedish Prescribed Drug Register between July and October 2005 (n = 645,429). Main outcome measure The hypnotic or sedative drug classes were benzodiazepines, benzodiazepine related drugs (i.e., Z-drugs) and other types of hypnotics or sedatives. The individual hypnotics or sedatives were nitrazepam, flunitrazepam, triazolam, zopiclone, zolpidem, clomethiazole and propiomazine. Results In the total study population, 27.1% of the women and 18.1% of the men were dispensed at least one hypnotic or sedative drug. The logistic regression analyses of those who used hypnotics or sedatives (n = 151,700) revealed that women were more likely than men to use benzodiazepines (adjusted OR = 1.11; 95% CI 1.07–1.14) and benzodiazepine related drugs (adjusted OR = 1.14; 95% CI 1.12–1.17), whereas men were more likely to use other types of hypnotics or sedatives (adjusted OR = 0.69; 95% CI 0.67–0.71). Among the individual hypnotics or sedatives, the strongest associations with gender was found for nitrazepam (adjusted OR = 1.19; 95% CI 1.14–1.25 for women compared with men), zolpidem (adjusted OR = 1.18; 95% CI 1.16–1.21), clomethiazole (adjusted OR = 0.48; 95% CI 0.46–0.51) and propiomazine (adjusted OR = 0.77; 95% CI 0.75–0.79). Conclusion Use of hypnotics or sedatives in old age seems to be related to female gender. Also, among elderly users of hypnotics or sedatives, women appear to be more likely to use benzodiazepines and benzodiazepine related drugs than men. The explanation to these gender differences merits further investigation.
Drug register Elderly Gender differences Hypnotics Sedatives Sweden
This is a preview of subscription content, log in to check access.
We thank Gunilla Ringbäck Weitoft for help with processing of the data material.
This study was supported financially by grants from the Swedish Council for Working Life and Social Research, the Swedish Research Council and Wolff’s Foundation at Karolinska Institutet.
Conflicts of interest
The authors have no conflicts of interest.
Hollingworth SA, Siskind DJ. Anxiolytic, hypnotic and sedative medication use in Australia. Pharmacoepidemiol Drug Saf. 2010;19:280–8.PubMedCrossRefGoogle Scholar
Johnell K, Fastbom J. The use of benzodiazpines and related drugs amongst older people in Sweden: associated factors and concomitant use of other psychotropics. Int J Geriatr Psychiatry. 2009;24:731–8.PubMedCrossRefGoogle Scholar
Linjakumpu T, Hartikainen S, Klaukka T, Koponen H, Kivela SL, et al. Psychotropics among the home-dwelling elderly–increasing trends. Int J Geriatr Psychiatry. 2002;17:874–83.PubMedCrossRefGoogle Scholar
Kjosavik SR, Ruths S, Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian prescription database. Pharmacoepidemiol Drug Saf. 2009;18:572–8.PubMedCrossRefGoogle Scholar
Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331:1169.PubMedCrossRefGoogle Scholar
Monane M, Glynn RJ, Avorn J. The impact of sedative-hypnotic use on sleep symptoms in elderly nursing home residents. Clin Pharmacol Ther. 1996;59:83–92.PubMedCrossRefGoogle Scholar
Sivertsen B, Omvik S, Pallesen S, Bjorvatn B, Havik OE, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA. 2006;295:2851–8.PubMedCrossRefGoogle Scholar
Allain H, Bentue-Ferrer D, Polard E, Akwa Y, Patat A. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging. 2005;22:749–65.PubMedCrossRefGoogle Scholar
Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M. Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. Health Technol Assess. 2004;8:1–68.Google Scholar
Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;281:991–9.PubMedCrossRefGoogle Scholar
van Hulten R, Leufkens HG, Bakker A. Usage patterns of benzodiazepines in a Dutch community: a 10-year follow-up. Pharm World Sci. 1998;20:78–82.PubMedCrossRefGoogle Scholar
Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18:425–32.PubMedGoogle Scholar
Foley DJ, Monjan A, Simonsick EM, Wallace RB, Blazer DG. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep. 1999;22(Suppl 2):S366–72.PubMedGoogle Scholar
Foley D, Ancoli-Israel S, Britz P, Walsh J. Sleep disturbances and chronic disease in older adults: results of the 2003 national sleep foundation sleep in America survey. J Psychosom Res. 2004;56:497–502.PubMedCrossRefGoogle Scholar
Newman AB, Enright PL, Manolio TA, Haponik EF, Wahl PW. Sleep disturbance, psychosocial correlates, and cardiovascular disease in 5201 older adults: the cardiovascular health study. J Am Geriatr Soc. 1997;45:1–7.PubMedGoogle Scholar
Giron MS, Forsell Y, Bernsten C, Thorslund M, Winblad B, et al. Sleep problems in a very old population: drug use and clinical correlates. J Gerontol A Biol Sci Med Sci. 2002;57:M236–40.PubMedCrossRefGoogle Scholar
Rediehs MH, Reis JS, Creason NS. Sleep in old age: focus on gender differences. Sleep. 1990;13:410–24.PubMedGoogle Scholar
Brownlee K, Devins GM, Flanigan M, Fleming JA, Morehouse R, et al. Are there gender differences in the prescribing of hypnotic medications for insomnia? Hum Psychopharmacol. 2003;18:69–73.PubMedCrossRefGoogle Scholar
Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, et al. The new Swedish prescribed drug register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726–35.PubMedCrossRefGoogle Scholar
Galobardes B, Lynch J, Smith GD. Measuring socioeconomic position in health research. Br Med Bull. 2007;81–82:21–37.PubMedCrossRefGoogle Scholar
Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854–64.PubMedCrossRefGoogle Scholar
Johnell K, Ringbäck Weitoft G, Fastbom J. Education and use of dementia drugs: a register-based study of over 600,000 older people. Dement Geriatr Cogn Disord. 2008;25:54–9.PubMedCrossRefGoogle Scholar
WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. International language for drug utilization research—ATC/DDD. http://www.whocc.no/ (2011). Accessed 7 June 2011.
Vrublevska K, Rukmane J, Burmistrs R, Sipols J, Muceniece R. Dispensing of psychotropic drugs to adults in community pharmacies in Latvia. Pharm World Sci. 2008;30:934–9.PubMedCrossRefGoogle Scholar
Schneeweiss S, Patrick AR, Sturmer T, Brookhart MA, Avorn J, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45:S131–42.PubMedCrossRefGoogle Scholar
McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf. 2003;12:551–8.PubMedCrossRefGoogle Scholar
Bulloch AG, Patten SB. Non-adherence with psychotropic medications in the general population. Soc Psychiatry Psychiatr Epidemiol. 2010;45:47–56.PubMedCrossRefGoogle Scholar